Bayer Aktiengesellschaft (ETR:BAYN)
Germany
· Delayed Price · Currency is EUR | Market Cap | 26.33B |
| Revenue (ttm) | 46.17B |
| Net Income (ttm) | -3.42B |
| Shares Out | 982.42M |
| EPS (ttm) | -3.48 |
| PE Ratio | n/a |
| Forward PE | 7.16 |
| Dividend | 0.11 (0.41%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 1,935,706 |
| Average Volume | 3,169,852 |
| Open | 26.89 |
| Previous Close | 26.80 |
| Day's Range | 26.53 - 26.90 |
| 52-Week Range | 18.38 - 31.03 |
| Beta | 0.99 |
| RSI | 48.36 |
| Earnings Date | Aug 6, 2025 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial StatementsNews
Why are Indoco Remedies shares up 2% today? Explained
Indoco Remedies Ltd shares climbed over 2% to ₹299.30 in morning trade on Tuesday after the company announced it has received final approval from the US Food and Drug Administration (USFDA) for its Ab...
Bayer and Kumquat Biosciences partner to develop cancer treatment
Bayer and Kumquat Biosciences Enter Global Exclusive License and Collaboration in Precision Oncology
BERLIN & SAN DIEGO--(BUSINESS WIRE)--Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced that they have entered into an exclus...
Bayer inks $1.3 billion deal with Kumquat Biosciences for cancer drug development
Bayer adds cancer drug candidate to portfolio with $1.3-billion Kumquat deal
German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.
Bayer, Kumquat Biosciences Team Up on New Potential Cancer Drug
Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will take the drug to market.
Bayer A.G. (BAYZF) Q2 2025 Earnings Call Transcript
Bayer A.G. 2025 Q2 - Results - Earnings Call Presentation
Bayer drops as core businesses underperform in Q2
Bayer AG Non-GAAP EPS of Є1.23, revenue of Є10.74B; raises FY outlook
Bayer says it has cut 12,000 jobs so far under restructuring push
Bayer said on Wednesday it had cut about 12,000 full-time positions since the start of a restructuring programme to speed up decision-making and reduce managerial and administrative positions.
Bayer Stock Is Soaring Ahead Of Its Earnings Release
Here's why the Bayer share price may rebound after earnings
Bayer share price pulled back to €27.6 on Tuesday as investors waited for its financial results. It has dropped by 7.3% from its highest level this year, and is about 50% above its lowest level this y...
Bayer gains after raising 2025 outlook
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Bayer Ups Guidance After Pharmaceuticals Unit Outperforms
Bayer increases Roundup litigation provisions by $1.37 billion
German pharmaceutical company Bayer said on Thursday it had set aside an additional 1.2 billion euros ($1.37 billion) in provisions to address ongoing Roundup litigation in the United States.
Bayer Boosts 2025 Forecast, Sets US Legal Provisions
Bayer's Pharmaceuticals division has exceeded expectations, prompting an optimistic revision of its 2025 financial outlook, with anticipated sales of up to 48 billion euros and a strong EBITDA forecas...
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer upgrades currency-adjusted sales and earnings guidance for 2025 and establishes additional provisions for litigation in the United States
EQS-Ad-hoc: Bayer Aktiengesellschaft / Key word(s): Half Year Report Bayer Aktiengesellschaft: Bayer upgrades currency-adjusted sales and earnings guidance for 2025 and establishes additional provisio...
French court finds complaint brought by family in Bayer glyphosate case inadmissible, media says
A French court ruled on Thursday that a complaint brought by a family against Bayer claiming their son's disabilities were the result of his mother's exposure to glyphosate when pregnant was inadmissi...
Bayer's Elinzanetant review period gets extended by FDA
US FDA extends review of Bayer's menopause relief drug
The U.S. Food and Drug Administration has extended its review of Bayer's experimental menopause relief drug, the German drugmaker said on Friday.
Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause.
Cory Booker pitches bill to allow lawsuits against pesticide makers over ‘toxic products’
Pesticide Injury Accountability Act would ensure that Bayer, Syngenta and others can be held responsible for allegedly causing health issues US politics live – latest updates Cory Booker on Thursday i...